News Conference News ACC 2024 Vaping Linked to Higher Risk of HFpEF, NIH Data Show L.A. McKeown April 12, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Conference News ACC 2024 Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF Michael O'Riordan April 06, 2024
News Conference News ACC 2023 How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA Todd Neale March 09, 2023
News Conference News ACC 2023 RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF Todd Neale March 05, 2023
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay Caitlin E. Cox May 16, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019